#USA #Irvine #CAR T-cell Therapy #B-cell Lymphoma #PeproMene Bio

PeproMene Bio's Groundbreaking CAR T-cell Therapy Published in The Lancet

Introduction

In a significant advancement in cancer treatment, PeproMene Bio, Inc. announced the publication of its Phase 1 clinical trial results in The Lancet, one of the most prestigious medical journals globally. This study focuses on the efficacy of PMB-CT01, a novel CAR T-cell therapy directed at the B-cell activating factor receptor (BAFF-R), specifically developed for patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The results are not only promising but represent a considerable leap forward for patients who have exhausted other treatment options, particularly those who have not responded to previous CD19-directed CAR T-cell therapies.

Key Trial Findings

The data revealed that 80% of the nine patients treated in the trial achieved a complete response (CR). This statistic is especially noteworthy given that four of six patients had previously experienced progression after receiving conventional CD19 CAR T-cell therapy. Remarkably, these complete responses have been sustained, with no relapses observed at the data cutoff, and the longest ongoing complete response lasting up to 35 months. Such outcomes suggest the potential for a cure, which is particularly encouraging for individuals with a previously dire prognosis.

Furthermore, PMB-CT01 displayed an attractive safety profile, with cytokine release syndrome (CRS) events and the neurotoxicity syndrome (ICANS) reported being limited to Grade 1. This indicates that the treatment is not only effective but also manageable for patients.

Expansion of Clinical Trials

Encouraged by these findings, PeproMene Bio is expanding its Phase 1 clinical trial from a single site at the City of Hope, an advanced cancer research and treatment organization, to several additional medical centers throughout the United States. Notably, the very first patient treated during this expansion phase—who was characterized by having triple-hit high-grade B-cell lymphoma—also experienced a complete response following initial assessment.

Significance of the Publication

Larry W. Kwak, M.D., Ph.D., the scientific founder of PeproMene Bio, emphasized the importance of this publication, asserting that it underscores the transformative potential of PMB-CT01 as a leading therapeutic option for blood cancers that were once considered untreatable. He elaborated on how the therapy's safety could pave the way for outpatient administration, ultimately enhancing accessibility for patients who have traditionally faced barriers to advanced cancer treatments. This expansion is crucial as it may lead to improved treatment strategies for autoimmune disorders where B-cell depletion has already shown promise.

Support and Future Directions

This groundbreaking work has gained significant financial backing, including a commitment from the Institute for Follicular Lymphoma Innovation (IFLI) of up to $11 million for the clinical development of PMB-CT01, particularly focusing on patients with relapsed or refractory follicular lymphoma. Dr. Mehrdad Mobasher, Executive Partner at IFLI, stated, "For patients whose lymphoma returns after CD19-directed CAR T-cell therapy, a new target can mean a new chance," indicating a shared enthusiasm regarding the future prospects of this innovative therapy.

Conclusions

The findings from PeproMene Bio's Phase 1 trial mark an important milestone in the treatment of difficult-to-manage B-cell lymphomas and underscore the company’s commitment to advancing cutting-edge therapies that address critical unmet medical needs. The early evidence of durability in response to treatment amplifies the hope for a paradigm shift in protocols dealing with blood cancers that have so far resisted standard therapeutic avenues. As the company continues to navigate clinical expansions and gather supportive evidence, the medical community watches with great anticipation the real-world effects of PMB-CT01 on patient outcomes.

For more information about PeproMene Bio and its innovative therapies, Dr. Hazel Cheng, COO, can be contacted at email protected] or by visiting [PeproMene Bio.